Efficacy of garlic (Allium sativum) on metabolic syndrome components in women with polycystic ovary syndrome: randomized controlled trial
Abstract
Background: This study aimed to illustrate the effect of garlic supplementation on metabolic syndrome (MetS) components in women with polycystic ovary syndrome (PCOS).
Methods: From 2020 to 2021, a randomized controlled clinical trial was conducted on 97 women with PCOS and MetS. Participants were randomly assigned to receive either garlic tablets (500 mg containing 2-3 mg allicin; n = 49) or placebo tablets (n = 48) twice daily for 8 weeks. The study assessed changes in MetS indices, quality of life (QoL), and sexual function before and after the intervention.
Results: After 8 weeks, the garlic group showed significant reductions in fasting blood sugar (FBS) by 10.5% (from 107.2 to 95.9 mg/dL; P < 0.001), triglycerides (TG) by 17.8% (P = 0.002), low-density lipoprotein cholesterol (LDL-C) by 14.2% (P < 0.001), total cholesterol (TC) by 12.6% (P < 0.001), and C-reactive protein (CRP) by 24.7% (P < 0.001), compared to the placebo group. A significant increase in sex hormone-binding globulin (SHBG) levels was also observed (18.3%; P = 0.005). Systolic and diastolic blood pressure decreased significantly by 5.2% and 6.1%, respectively (P < 0.001 and P = 0.001), and both weight and body mass index (BMI) were significantly reduced (P < 0.01). However, the waist-to-hip ratio (WHR) did not change significantly (P = 0.86). Notable improvements were also observed in all six domains of the Female Sexual Function Index (FSFI)- desire, arousal, lubrication, orgasm, satisfaction, and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 97 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.